Tasked with delivering a life-saving pharmaceutical to combat opioid exposures, the ROCS team not only delivered a therapeutic, but also a prophylaxis. This lifesaving capability limits the risk of military personnel and first responders becoming non-ambulatory due to opioid exposure. Using innovative strategies and partnering with kaléo, the team accomplished their goals ahead of schedule and under budget, satisfying both demanding DoD acquisition criteria and FDA regulatory processes.